Moderate‐potency vs mild‐potency topical corticosteroid
Systemic adverse events: abnormal cortisol; end of treatment (1‐6 weeks) · children and adults with mild to severe eczema
It is very uncertain whether moderate‐potency changes systemic adverse events: abnormal cortisol; end of treatment (6‐28… compared with mild‐potency topical corticosteroid (very low certainty).
1 finding from 1 review
- Strategies for using topical corticosteroids in children and adults with eczema 2022 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 33 participantsVery low